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Abstract
Introduction: We wanted to assess the importance of the levels of anti-citrullinated peptide antibody (anti-CCP) and 
immunoglobulin M (IgM) rheumatoid factor (RF) in predicting development of persistent arthritis from 
undifferentiated arthritis (UA), and to investigate whether there is an added predictive value for persistent arthritis in 
testing for both anti-CCP and IgM RF.
Methods: Patients with UA (exclusion of definite non-rheumatoid arthritis (RA) diagnoses) included in the Norwegian 
very early arthritis clinic were assessed for development of persistent arthritic disease. The effect of antibody level on 
the likelihood of persistent arthritis was investigated, and the sensitivity and specificity for persistent arthritis for anti-
CCP and IgM RF, separately and combined, was determined.
Results: A total of 376 UA patients were included (median arthritis duration 32 days). 59 (15.7%) patients were IgM RF 
positive, and 62 (16.5%) anti-CCP positive. One hundred, seventy-four (46.3%) had persistent disease after one year. 
Overlap of anti-CCP and IgM RF positivity was 58%. Sensitivity/specificity for persistent arthritis was 28/95% for IgM RF 
alone, 30/95% for anti-CCP alone, and 37/92% for positivity of both anti-CCP and IgM RF. The likelihood for persistent 
disease increased with increasing levels of both anti-CCP and IgM RF.
Conclusions: The likelihood of developing persistent arthritis in UA patients increases with the level of anti-CCP and 
IgM RF. Testing both anti-CCP and IgM RF has added predictive value in UA patients. This study suggests that antibody 
level should be taken into account when making risk assessments in patients with UA.
Introduction
Rheumatoid factor (RF) has traditionally been regarded
as the main serologic marker in inflammatory arthritis
[1,2]. In recent years anti-citrullinated protein antibodies
(ACPA), most commonly measured by assays for anti-
bodies against cyclic citrullinated peptide (anti-CCP),
have also been identified as important predictors both for
diagnosis and prognosis in rheumatoid arthritis (RA)
[3,4]. RF has similar sensitivity as anti-CCP in RA diagno-
sis but lower specificity [3,5-8], and RF and anti-CCP are
both independent predictors of erosive progression [9].
The paradigm of a window of opportunity in the treat-
ment of inflammatory arthritis has raised awareness of
seeing patients at the earliest possible stage of disease.
The 1987 American Rheumatism Association (ARA)
classification criteria for RA [1] do not perform well in
early disease [10] and early arthritis is often undifferenti-
ated and may develop into RA [11,12]. A few studies have
identified anti-CCP or RF as predictors of persistent
arthritis (as opposed to remission of disease) [13-17].
* Correspondence: maria_mjaavatten@hotmail.com
1 Department of Rheumatology, Diakonhjemmet Hospital, P.O. Box 23 
Vinderen, 0319 Oslo, Norway
Full list of author information is available at the end of the articleBioMed Central
© 2010 Mjaavatten et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Mjaavatten et al. Arthritis Research & Therapy 2010, 12:R76
http://arthritis-research.com/content/12/3/R76
Page 2 of 9Several questions remain unanswered regarding the
predictive role of anti-CCP and RF in patients with early
undifferentiated arthritis. What is the optimal cut-off
level for defining a positive antibody status? Is a high pos-
itive level of anti-CCP or RF more predictive of an unfa-
vourable outcome than a low positive level? What is the
added value (if any) of testing for both markers? Regard-
ing the optimal cut-off of anti-CCP level, a recent study
on pre-RA sera [18] suggested that lowering thresholds
below that of the manufacturer's recommended cut-off
level gave more sensitive prediction of future RA devel-
opment. Increased levels of ACPA are associated with
worse radiographic progression and higher disease activ-
ity in RA [9,19,20], whereas no such relationship was
found in a recent study of prognosis in early arthritis
patients [21]. No studies have assessed the predictive
value of the levels of anti-CCP and RF in patients with
early undifferentiated arthritis.
The objectives of this study were 1) to investigate
whether there is an added predictive value for persistent
arthritis in testing for both anti-CCP and IgM RF and 2)
to assess the predictive performance for persistent arthri-
tis of the level of anti-CCP and RF in patients with arthri-
tis duration <16 weeks.
Materials and methods
Early arthritis clinic
The Norwegian Very Early Arthritis Clinic (NOR-VEAC)
study was started in 2004 as a multicenter observational
study in the South-Eastern part of Norway. The five par-
ticipating hospitals serve a region with approximately 1.7
million inhabitants. The cohort includes patients (age 18
to 75) presenting with at least one clinically swollen joint
of ≤ 16 weeks duration, and patients are followed longitu-
dinally for two years. One year outcome was used in the
present study.
Joint swelling due to trauma, osteoarthritis, crystal
arthropathies, and septic arthritis are exclusion diagno-
ses; if any of these diagnoses are made during follow-up,
patients are excluded from further follow-up. The details
of the data collection have been described elsewhere [22],
and are summarised in Additional file 1. Imaging proce-
dures were not a part of the data collection for the
patients included in this analysis. The study was
approved by the regional Ethics Board and the Data
Inspectorate, and patients gave an informed consent.
Laboratory markers
Erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein levels were determined locally at the participating
centres. Serum was frozen at baseline and stored at -70°C
and used to analyse anti-citrullinated protein antibodies
(ACPA) (anti-CCP2, INOVA Diagnostics, Inc.® San Diego,
CA, USA) and IgM rheumatoid factor (RF) (in-house
enzyme-linked immunosorbent assay) [9]. Analyses of
the serologic markers were performed in one batch. Anti-
CCP levels were reported in units from 2 to 250. Any
level greater than 250 was reported as >250 and analysed
as 251, and levels less than 2 were reported as <2 and
analysed as 1. Similarly, IgM RF levels were reported in
units from 2 to 300. Any level greater than 300 was
reported as >300 and analysed as 301, and levels less than
2 were reported as <2 and analysed as 1. The cut-off levels
recommended by the central laboratory for positivity of
the serologic markers are: Anti-CCP2 ≥ 25 units/ml, IgM
RF ≥ 25 units/ml [9].
Patient selection and outcome determination
Patients included before 1 June 2007, who had baseline
information about IgM RF and anti-CCP, were eligible for
the current analysis. Patients who were judged by the
treating rheumatologist to have a definite diagnosis other
than RA were excluded from the present analysis, leaving
only patients with very early undifferentiated arthritis in
the study. Persistent arthritis (the outcome) was defined
as presence of joint swelling at one year. For patients lost
to follow-up before one year, the last registered follow-up
visit was used in a last observation carried forward
(LOCF) manner with regard to joint swelling, provided
that at least one follow-up visit was recorded. Patients
prescribed with disease-modifying anti-rheumatic drug
(DMARD) therapy within one year of presentation were
also included in the persistent arthritis group. To deter-
mine whether it was correct to include these DMARD-
starting patients in the persistent arthritis group, baseline
characteristics were compared between patients with
persistent synovitis (with or without concomitant
DMARD prescription) and patients in which DMARDs
were prescribed without coexisting persistent arthritis.
Statistical analysis
Means and standard deviations were calculated for con-
tinuous variables following a Gaussian distribution, oth-
erwise median values and inter quartile ranges (25th to
75th percentiles) were calculated. Independent samples T-
tests/Mann-Whitney-U tests were used for group com-
parisons where appropriate. Frequencies were calculated
for categorical variables and compared using Chi-square
tests.
The relationship between anti-CCP as a continuous/
dichotomised variable and the outcome (persistent
arthritis) was investigated through univariate and subse-
quently multivariate logistic regression analyses. The
multivariate analyses were adjusted for factors previously
found to affect the outcome (age, sex, small joint arthritis,
functional status according to Health Assessment Ques-
tionnaire (HAQ) score, 28-tender joint count, C-reactive
protein, morning stiffness >1 hour) [13,16,23]. IgM RF
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receiver operating characteristic (ROC) curve analysis.
ROC curve analysis was also used to investigate whether
alternative cut-offs had more optimal combined sensitiv-
ity/specificity than the recommended cut-off of 25 units/
ml. Likelihood ratios and their 95% confidence intervals
were calculated for these alternative cut-offs.
To assess the effect of increasing levels of anti-CCP and
IgM RF on the likelihood of developing persistent disease,
anti-CCP and IgM RF levels were divided into ordinal
categories (based on the recommended cut-off as well as
with tertiles/median of antibody positive patients for
anti-CCP and IgM RF, respectively). This resulted in two
new, categorized variables (anti-CCP: ≤ 25, >25 to 100,
>100 to 250, >250 units/ml; IgM RF: ≤ 25, >25 to 75, >75
units/ml), and these variables were entered into separate
univariate logistic regression models. Likelihood ratios
for each of the categories compared to the reference cate-
gory (≤ 25 units/ml) were calculated. The prediction
models were also tested in each subgroup of patients with
persistent disease (persistent synovitis or DMARD pre-
scription alone) as a sensitivity analysis.
Results
Baseline information about anti-CCP and IgM RF was
available in 483/572 (84%) patients enrolled in the study.
Patients with and without available sera were similar
regarding baseline characteristics and outcome (data not
shown). Eighty-nine patients were excluded from the
analysis because they were diagnosed with a specific
rheumatological non-RA condition at the initial assess-
ment (Löfgren's syndrome/sarcoidosis-associated arthri-
tis 39, psoriatic arthritis according to the Moll & Wright
criteria for psoriatic arthritis (PsA) [24] 38, gout 10,
ulcerative colitis-arthritis 1, polymyalgia rheumatica 1).
Further, 18 patients were excluded from analysis because
they had no follow-up data recorded, leaving 376 patients
with very early undifferentiated inflammatory arthritis
for the current analysis.
Baseline characteristics of the 376 patients are pre-
sented in Table 1. The baseline data were complete except
for some missing data for morning stiffness. Median
(interquartile range, IQR) anti-CCP level in the 62
(16.5%) patients who were anti-CCP2 positive (cut-off 25
units/ml) was 205 (76 to 251) units/ml. Fifty-nine (15.7%)
patients were IgM RF positive (>25 units/ml), with
median (IQR) IgM RF level 69 (44 to 125) units/ml).
Twenty-one patients were solely anti-CCP positive and
18 solely RF positive, while 41 patients were positive for
both serologic markers. One hundred seventy-four
(46.3%) patients had persistent disease after one year
(persistent joint swelling 65, DMARD prescribed 52, both
57). In 32 patients the outcome was determined by the
LOCF strategy due to missing data (persistent arthritis 9,
remission 23). The DMARDs prescribed were distributed
as follows: methotrexate 72 (66.1%) patients, sulphasala-
zine 21 (19.3%), hydroxychloroquine 4 (3.7%), biologics
(+ methotrexate) 5 (1.3%), combinations of traditional
DMARDs 5 (1.3%), other 2 (0.5%) patients. Patients with
and without persistent disease at one year differed signifi-
cantly with respect to several baseline characteristics
(Table 1).
Associations between persistent disease and the serologic 
markers
Logistic regression analyses showed significant univariate
associations with persistent disease for anti-CCP and
IgM RF which were maintained in the multivariate analy-
sis (Table 2). The odds ratios for persistence were almost
doubled when both serologic markers were present.
The distribution of anti-CCP- and RF positive patients
with and without persistent disease is shown in Table 3.
Only 58% (37/64) of antibody positive patients with per-
sistent arthritis were positive for both RF and anti-CCP.
Testing for only anti-CCP would identify 52 of the 174
patients (sensitivity 30%) with persistent arthritis. Speci-
ficity was 95.0%. Testing for only IgM RF would identify
slightly fewer patients, 49/174 (sensitivity 28%), with
equal specificity as for anti-CCP alone (95.0%). Testing
for both markers would identify 64/174 patients (sensitiv-
ity 37%). The number of false-positives for anti-CCP and
RF combined was 16 patients, yielding a specificity of
92.1% for the and/or combination. A serial measuring
strategy starting with measuring IgM RF would not iden-
tify 21/80 (26.3%) autoantibody positive patients, and 15/
174 (8.6%) of patients with persistent arthritis would be
missed.
ROC curve analysis and alternative cut offs
The ROC curve analysis showed moderate discrimina-
tory capacity of anti-CCP (Figure 1), with an area under
the curve (AUC) of 0.69. The combination of slightly
increased accuracy and positive likelihood ratios remain-
ing above 4 suggested some gain in informative value of
lowering the threshold down to about 50% of the recom-
mended cut-off for anti-CCP (Table 4). The ROC curve
analysis for IgM RF showed slightly less discriminatory
capacity than anti-CCP, with an AUC of 0.64 (Figure 1).
Lowering the threshold for defining a positive status for
RF resulted in a rather large loss of specificity and posi-
tive likelihood ratio (LR) with little gain in sensitivity or
negative LR (Table 4).
Effect of increasing antibody levels
When patients were divided into categories based on
anti-CCP level (as described in the Methods section) the
numbers of patients in each category were as follows: ≤
25 units/ml (n = 314), >25 to 100 units/ml (n = 19), >100
to 250 units/ml (n = 14), >250 units/ml (n = 29). The like-
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Table 1: Baseline characteristics of the patients with comparison between patients with/without persistent arthritis at one year
All patients
(n = 376)
Persistent disease
(N = 174)
Self-limiting disease
(N = 202)
P*
Persistent synovitis
(with or without DMARD)
(N = 122)
DMARD prescribed
(without persistent synovitis)$
(N = 52)
Female gendera 218 (58.0) 78 (63.9) 32 (61.5) 108 (53.5) 0.06
Age, yearsb 46.3 (14.8) 49.0 (14.9) 45.6 (17.1) 44.9 (14.0) 0.04
Arthritis duration, daysc 32 (10 to 64) 50 (21 to 69) 59 (27 to 76) 21 (7 to 49) <0.001
SJC (0 to 68)c 2 (1 to 5) 4 (1 to 9) 4 (2 to 8) 1 (1 to 3) <0.001
TJC (0 to 28)c 1 (1 to 3) 2 (1 to 6) 2 (1 to 5) 1(0 to 2) <0.001
ESR, mm/hc 24 (11 to 46) 27 (10 to 50) 32 (17 to 51) 19 (10 to 38) 0.005
CRP, mg/lc 15.0 (5.0 to 36.4) 15 (5 to 35) 18 (9 to 45) 14.0 (3.5 to 36.2) 0.16
IgM RF level, units/mlc 4 (1 to 10) 6 (2 to 40) 6 (2 to 30) 3 (1 to 7) <0.001
IgM RF positivea 59 (15.7) 36 (29.5) 13 (25.0) 10 (5.0) <0.001
Anti-CCP2 level, units/mlc 3 (2 to 6) 4 (2 to 83) 4 (2 to 25) 2 (2 to 4) <0.001
Anti-CCP2 positivea 62 (16.5) 39 (32.0) 13 (25.0) 10 (5.0) <0.001
Assessor's global VAS, mmb 35.8 (20.7) 39.5 (21.8) 44.7 (23.0) 31.3 (18.2) <0.001
Patient's global VAS, mmb 53.8 (24.0) 57.4 (21.9) 59.5 (26.1) 50.2 (24.1) 0.001
Small joint arthritisa 173 (46.0) 73 (59.8) 33 (63.5) 67 (33.2) <0.001
Morning stiffness>1 houra 195 (51.9)§ 70 (57.9) 31 (60.8) 101 (58.0) 0.04
DAS28b 4.05 (1.32) 4.47 (1.35) 4.61 (1.36) 3.65 (1.15) <0.001
HAQ (0-3)b 0.89 (0.67) 0.98 (0.64) 1.07 (0.80) 0.78 (0.63) 0.001
Monoarthritisa 154 (41.0) 37 (30.3) 12 (23.1) 105 (52.0) <0.001
-of the kneea 80 (51.9) 20 (54.1) 6 (50.0) 54 (51.4) 0.85
Fulfilment of 1987 ACR criteriaa† 70 (18.6) 37 (30.3) 16 (30.8) 17 (8.4) <0.001
ACR: American College of Rheumatology; anti-CCP2: 2nd generation anti-citrullinated peptide antibody; CRP: C-reactive protein; DAS: Disease Activity Score; ESR: erythrocyte sedimentation 
rate; HAQ: Health Assessment Questionnaire; RF: rheumatoid factor; SJC: swollen joint count; TJC: tender joint count; VAS: visual analogue scale; small joint arthritis, joint swelling in PIP-, MCP- 
or MTP joint(s).
$No statistical differences between the persistent arthritis group and DMARD group for any of the baseline variables were found.
*Comparing persistent disease group with self-limiting disease group.aCount (%).bMean (standard deviation).cMedian (inter-quartile range).§N = 369.†Modified from the 1987 ARA criteria 
according to available data (excluding criteria on erosive disease and duration of symptoms).
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with increasing levels of anti-CCP (Table 5), suggesting
that the level of ACPA can be informative in prediction of
persistent arthritis.
Similarly, the numbers of patients in each of the catego-
ries for IgM RF level were: ≤ 25 units/ml (n = 317), >25 to
75 units/ml (n = 32), >75 units/ml (n = 27). As for anti-
CCP, increasing levels of IgM RF were associated with
higher positive likelihood of developing persistent arthri-
tis. The negative likelihood ratios for all cut-offs were
rather high but consistent with increasing levels. Sensitiv-
ity analyses with DMARD start alone or persistent syno-
vitis alone as outcome did not change these results.
Discussion
This study is the first to show that the likelihood of per-
sistent arthritis increases with the levels of IgM RF and
anti-CCP. We also demonstrate an added predictive value
in testing for both biomarkers in patients with very early
undifferentiated arthritis. Several studies have assessed
anti-CCP and/or RF as predictors of persistent arthritic
disease in patients with undifferentiated arthritis
[7,13,15-17] but none of these investigated the influence
of antibody level on diagnostic outcome. The association
between levels of these serologic markers and outcome
also supports the new American College of Rheumatol-
ogy (ACR)/European League Against Rheumatism
(EULAR) classification criteria for RA which provide dif-
ferent points in the classification system according to
level of anti-CCP or RF. (Aletaha D, et al. The 2010
American College of Rheumatology/European League
Against Rheumatism Classification Criteria for Rheuma-
toid Arthritis. Arthritis Rheum/Ann Rheum Dis 2010,
submitted.)
When working with prediction models, the challenge of
circularity arises when the predictive factor is a part of
diagnostic or classification criteria. Presence of the factor
of interest can bias the physician to label or diagnose a
patient (for example, rheumatoid factor or anti-CCP and
RA) [13,25]. This challenge can be overcome by using
alternative definitions of the outcome, like persistent
joint swelling or erosive disease, which are examples of
more objective outcomes in early arthritis patients. Their
determination relies solely on the presence of physical
features, and therefore is less likely to be biased. More-
over, 17 patients who fulfilled the 1987 ARA criteria for
Table 2: Logistic regression analysis exploring the relationship between anti-CCP/IgM RF and persistent arthritic disease
Univariate Multivariate*
estimate OR
(95% CI)
P estimate OR
(95% CI)
P
Anti-CCP2
(units/ml)
0.013 1.013
(1.008 to 1.018)
<0.001 0.008 1.008
(1.003 to 1.013)
0.002
Anti-CCP2+
(>25 units/ml)
2.102 8.184
(4.008 to 16.709)
<0.001 1.272 3.567
(1.572 to 8.094)
0.002
IgM RF (units/ml) 0.022 1.022
(1.012 to 1.033)
<0.001 0.009 1.009
(1.001 to 1.017)
0.026
IgM RF+ (>25 units/ml) 2.018 7.526
(3.677 to 15.407)
<0.001 0.999 2.716
(1.189 to 6.202)
0.018
IgM RF+ and anti-CCP+ 2.593 13.369
(4.658 to 38.369)
<0.001 2.073 7.948
(2.659 to 23.752)
<0.001
*Adjusted for age, sex, small joint arthritis (swelling of MTP-, PIP- and/or MCP joints), Health Assessment Questionnaire, 28-tender joint count, 
C-reactive protein (mg/l), morning stiffness >1 hour, as well as IgM rheumatoid factor (for the analysis with anti-CCP) or anti-CCP (for the 
analysis with IgM RF), respectively.
Table 3: Distribution of anti-CCP- and IgM RF positive patients with/without persistent arthritis
Persistent arthritis Self-limiting disease Total
Anti-CCP positive only 15 6 21
Anti-CCP and IgM RF positive 37 4 41
IgM RF positive only 12 6 18
No antibody positivity 110 186 296
Total 174 202 376
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after one year (Table 1), which is in line with previous
early arthritis studies demonstrating the low specificity of
these criteria [10,26-28].
As evidence of the superior specificity and similar sen-
sitivity of anti-CCP as compared to RF as a predictor of
an adverse outcome in inflammatory arthritis has
increased [3,5-7], the question of whether one should
stop testing for RF has been raised [29]. The overlap
between RF and anti-CCP positivity may be greater in
established RA (93% in a study of 784 RA patients, mean
disease duration 18 years) [30], than in early arthritis (50
to 80% in different studies) [5,7,31]. In the present study
only 58% (37/64) of antibody positive patients with per-
sistent arthritis were positive for both RF and anti-CCP.
Testing for both markers increased sensitivity for persis-
tent arthritis from about 30% to 37%. Our results support
that each of these antibodies should be evaluated when
making risk assessments in early arthritis, especially if the
one first tested is negative.
We also investigated the benefits and drawbacks of low-
ering the threshold for defining a positive antibody status.
Although lowering the threshold resulted in a rather
steep loss of specificity for IgM RF, we found some, but
limited, added predictive value of lowering the threshold
for anti-CCP positivity to 10 units/ml. This is in line with
the findings in a recent study [18]. We believe that the cli-
nician should be aware of the potential value also of low
Table 4: Sensitivity, specificity, and likelihood ratios for persistent arthritis for different minimum cut-off levels for anti-
CCP2 and IgM RF
Cut-off anti-CCP2
(units/ml)
Sensitivity Specificity Accuracy LR+
(95% CI)
LR-
(95% CI)
2 0.71 0.55 0.63 1.59 (1.32 to 1.91) 0.53 (0.41 to 0.69)
3 0.58 0.72 0.65 2.06 (1.60 to 2.65) 0.58 (0.48 to 0.71)
4 0.47 0.80 0.65 2.38 (1.73 to 3.27) 0.66 (0.56 to 0.77)
5 0.43 0.87 0.67 3.23 (2.18 to 4.77) 0.66 (0.57 to 0.77)
10 0.35 0.93 0.66 4.98 (2.88 to 8.58) 0.71 (0.69 to 1.79)
15 0.32 0.95 0.66 5.91 (3.20 to 10.92) 0.72 (0.64 to 0.80)
20 0.31 0.95 0.65 5.59 (3.02 to 10.37) 0.74 (0.66 to 0.82)
25 0.30 0.95 0.64 6.04 (3.17 to 11.51) 0.74 (0.67 to 0.82)
Cut-off IgM RF
(units/ml)
Sensitivity Specificity Accuracy LR+ LR-
2 0.71 0.41 0.55 1.20 (1.04 to 1.39) 0.71 (0.53 to 0.94)
3 0.62 0.54 0.58 1.34 (1.13 to 1.65) 0.70 (0.55 to 0.88)
5 0.51 0.69 0.61 1.67 (1.30 to 2.15) 0.71 (0.59 to 0.84)
7 0.43 0.77 0.61 1.85 (1.37 to 2.51) 0.74 (0.64 to 0.86)
10 0.33 0.87 0.62 2.49 (1.66 to 3.76) 0.77 (0.68 to 0.87)
15 0.31 0.92 0.64 3.69 (2.22 to 6.12) 0.75 (0.68 to 0.84)
20 0.29 0.95 0.64 5.28 (2.84 to 9.81) 0.75 (0.68 to 0.83)
25 0.28 0.95 0.64 5.69 (2.97 to 10.89) 0.76 (0.69 to 0.83)
CI: confidence interval; LR+: positive likelihood ratio; LR-: negative likelihood ratio.
Figure 1 Receiver operating characteristic curve analysis. Receiv-
er operating characteristic (ROC) curve analysis investigating the dis-
criminatory capacity for persistent arthritis at one year of baseline 
antibody levels. Area under the curve (AUC) (95% confidence interval): 
Anti-CCP: 0.687 (0.633 to 0.742), IgM RF: 0.641 (0.585 to 0.697).
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patients, but we cannot recommend a change in the cur-
rent threshold for positivity based on our findings.
Is there a dose-response relationship between antibody
level and likelihood of developing persistent arthritis?
Kudo-Tanaka and colleagues reported a higher mean
level of anti-CCP2 (Axis-Shield Diagnostics Ltd., Dundee,
Scotland, cut-off 4.6 U/ml for positive status) in patients
developing RA (167 U/ml) than in patients developing
other arthropathies or persistent UA (55 U/ml) in a study
of 146 anti-CCP positive UA patients [32]. A Dutch study
of patients with arthralgia demonstrated higher median
levels of ACPA and IgM RF in patients developing arthri-
tis than in patients who did not [33]. Our findings sup-
port that patients with very high levels of anti-CCP or
rheumatoid factor are more prone to enter a serious dis-
ease course than individuals with low positive levels. This
study is the first to demonstrate the effect of levels of
anti-CCP and IgM RF on the likelihood of persistent dis-
ease, although the numbers of patients with a positive
antibody status is moderate and the confidence intervals
for the point estimates are wide. A dose-response rela-
tionship could support the theory of a pathophysiologic
role for anti-CCP antibodies in the development of RA
and persistent arthritic diseases, but further studies are
needed to shed more light on this complex issue. Impor-
tantly, our study supports that presence of high antibody
levels give more points than low levels in the new ACR/
EULAR classification criteria for RA.
We have shown in this and a previous report [23] that
anti-CCP is the most important predictor of an adverse
outcome in early arthritis. However, as most patients who
developed persistent disease were antibody negative, it is
important to bear in mind that early referral and assess-
ment is needed in all patients with significant inflamma-
tory arthritis.
Conclusions
This study of persistent arthritis in patients with arthritis
of less than 16 weeks' duration demonstrates that high
positive levels of IgM RF and anti-CCP, as compared to
low positive levels increase the likelihood of developing
chronic arthritic disease, and also suggests an added
value of testing for both antibodies in early disease. We
conclude that antibody level should be taken into account
when making risk assessments in patients with early
undifferentiated arthritis.
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receiver operating characteristic; SJC: swollen joint count; TJC: tender joint
count; UA: undifferentiated arthritis; VAS: visual analogue scale
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Table 5: Univariate logistic regression for persistent arthritis with anti-CCP/IgM RF as categorical (grouped) variables 
according to level
Anti-CCP (units/ml) OR (95% C.I.) P LR+ LR- Persistent arthritis patients/
patients in category
n/N
≤ 25 1.0 ref ref 122/314 (38.9%)
>25 to 100 4.4 (1.6 to 12.5) 0.005 4.1 (1.5 to 11.0) 0.9 (0.9 to 1.0) 14/19 (73.7%)
>100 to 250 9.4 (2.1 to 42.9) 0.004 8.7 (2.0 to 38.2) 0.9 (0.8 to 1.0) 12/14 (85.7%)
>250 13.6 (4.0 to 46.0) <0.001 11.4 (3.5 to 37.0) 0.8 (0.8 to 0.9) 26/29 (89.7%)
IgM RF (units/ml) OR (95% C.I.) P LR+ LR-
≤ 25 1.0 ref ref 125/317 (39.4%)
>25 to 75 4.6 (2.0 to 10.6) <0.001 4.0 (1.9 to 8.7) 0.9 (0.8 to 0.9) 24/32 (75.0%)
>75 19.2 (4.5 to 82.5) <0.001 16.2 (3.9 to 67.2) 0.8 (0.8 to 0.9) 25/27 (92.6%)
CI: confidence interval; LR+: positive likelihood ratio; LR-: negative likelihood ratio; OR, odds ratio
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